NBIX

+ Watchlist + Portfolio

Neurocrine Biosciences, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $155.54
52-Week Range: $122.14 – $186.12
Market Cap: $15.55B
P/E (TTM): 22.36
EPS (TTM): 6.84
Dividend Yield: —

Advanced Metrics

Price/Book: 4.21
PEG Ratio: 0.46
Return on Equity: 22.09%
Return on Assets: 11.70%
Gross Margin: 64.48%
Operating Margin: 22.19%
Profit Margin: 20.91%
Current Ratio: 1.87
Debt/Equity: 0.12
Total Debt: $461.60M
Free Cash Flow: $638.24M
Revenue Growth: 39.50%
Earnings Growth: 31.10%
Enterprise Value: $15.88B

NBIX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.49B	$1.89B	$2.36B	$2.86B
Cost of Revenue	$23.20M	$39.70M	$34.00M	$52.10M
Gross Profit	$1.47B	$1.85B	$2.32B	$2.81B
Research & Development	$463.80M	$565.00M	$731.10M	$1.02B
Selling, General & Admin	$752.70M	$887.60M	$1.01B	$1.16B
Operating Expenses	$1.22B	$1.45B	$1.74B	$2.17B
Operating Income	$249.00M	$394.80M	$583.00M	$636.50M
EBITDA	$264.60M	$416.10M	$639.70M	$666.60M
Pretax Income	$213.90M	$332.10M	$486.00M	$705.40M
Income Tax	$59.40M	$82.40M	$144.70M	$226.80M
Net Income	$154.50M	$249.70M	$341.30M	$478.60M
Diluted EPS	1.56	2.47	3.29	4.67
Diluted Shares	98.90M	101.00M	103.70M	102.50M

NBIX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$262.90M	$251.10M	$233.00M	$713.00M
Receivables	$350.00M	$439.30M	$479.10M	$686.80M
Inventory	$35.10M	$38.30M	$57.40M	$69.00M
Current Assets	$1.45B	$1.61B	$1.72B	$2.52B
Total Assets	$2.37B	$3.25B	$3.72B	$4.63B
Current Liabilities	$537.70M	$654.80M	$507.70M	$743.40M
Total Debt	$262.90M	$428.40M	$455.10M	$415.30M
Total Liabilities	$660.90M	$1.02B	$1.13B	$1.38B
Retained Earnings	-$406.80M	-$157.10M	$29.20M	$447.70M
Shareholders' Equity	$1.71B	$2.23B	$2.59B	$3.25B
Working Capital	$915.80M	$952.20M	$1.22B	$1.78B

NBIX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$339.40M	$389.90M	$595.40M	$782.70M
Capital Expenditure	-$16.50M	-$28.30M	-$38.20M	-$34.00M
Free Cash Flow	$322.90M	$361.60M	$557.20M	$748.70M
Depreciation & Amortisation	$15.60M	$21.30M	$27.10M	$30.10M
Stock-Based Compensation	$173.10M	$194.30M	$195.50M	$217.90M
Investing Cash Flow	-$177.10M	-$467.10M	-$126.80M	-$264.40M
Financing Cash Flow	-$234.30M	$65.30M	-$486.70M	-$38.30M
Share Repurchases	$0.00	$0.00	-$300.00M	-$167.70M
Net Change in Cash	-$72.00M	-$11.90M	-$18.10M	$480.00M

NBIX Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$687.50M	$794.90M	$805.50M	$814.50M	$959.00M
Cost of Revenue	$10.30M	$14.00M	$17.60M	$13.80M	$23.20M
Gross Profit	$677.20M	$780.90M	$787.90M	$800.70M	$935.80M
Research & Development	$244.30M	$250.00M	$258.20M	$296.20M	$326.70M
Selling, General & Admin	$286.30M	$291.60M	$301.80M	$318.50M	$439.70M
Operating Expenses	$531.60M	$541.60M	$560.00M	$614.70M	$782.80M
Operating Income	$145.60M	$239.30M	$227.90M	$186.00M	$153.00M
EBITDA	$166.80M	$247.00M	$235.40M	$193.30M	$189.90M
Pretax Income	$159.50M	$291.80M	$239.40M	$246.80M	$162.20M
Income Tax	$52.00M	$82.30M	$85.70M	$48.90M	$17.80M
Net Income	$107.50M	$209.50M	$153.70M	$197.90M	$144.40M
Diluted EPS	1.06	2.04	1.48	1.91	1.39
Diluted Shares	101.00M	102.50M	103.70M	103.40M	104.20M

NBIX Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$264.00M	$340.20M	$713.00M	$266.50M	$332.40M
Receivables	$595.70M	$728.00M	$686.80M	$768.10M	$887.00M
Inventory	$56.90M	$69.30M	$69.00M	$64.50M	$104.20M
Current Assets	$1.75B	$2.16B	$2.52B	$2.44B	$1.64B
Total Assets	$3.89B	$4.27B	$4.63B	$4.91B	$5.36B
Current Liabilities	$546.30M	$638.00M	$743.40M	$831.70M	$874.50M
Total Debt	$439.10M	$428.40M	$415.30M	$406.20M	$401.80M
Total Liabilities	$1.20B	$1.26B	$1.38B	$1.50B	$1.67B
Retained Earnings	$84.50M	$294.00M	$447.70M	$589.60M	$724.00M
Shareholders' Equity	$2.69B	$3.00B	$3.25B	$3.41B	$3.69B
Working Capital	$1.20B	$1.52B	$1.78B	$1.60B	$763.00M

NBIX Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$102.00M	$227.50M	$388.40M	$145.80M	$136.40M
Capital Expenditure	-$12.50M	-$13.20M	—	-$9.10M	-$7.80M
Free Cash Flow	$89.50M	$214.30M	$390.80M	$136.70M	$128.60M
Depreciation & Amortisation	$7.30M	$7.70M	$7.50M	$7.30M	$24.80M
Stock-Based Compensation	$52.80M	$53.70M	$58.60M	$57.20M	$65.00M
Investing Cash Flow	-$29.00M	-$196.70M	-$52.90M	-$506.20M	-$135.40M
Financing Cash Flow	-$3.30M	$45.60M	$37.30M	-$86.10M	$63.40M
Share Repurchases	-$17.70M	$0.00	$0.00	-$54.00M	-$12.00M
Net Change in Cash	$69.70M	$76.40M	$372.80M	-$446.50M	$64.40M

Market Snapshot

About

Neurocrine Biosciences, Inc. discovers and develops treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company markets INGREZZA for tardive dyskinesia and develops a pipeline targeting conditions like schizophrenia, endometriosis, and congenital adrenal hyperplasia. Neurocrine focuses on diseases with significant unmet medical needs where neurological pathways play a central role.